Crinetics Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 73,000 shares of its common stock to nine new non-executive employees

Crinetics Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 112,500 shares of its common stock to eight new non-executive employees

Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference


Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome


Crinetics announces positive initial findings from its ongoing open-label Phase 2 carcinoid syndrome study of paltusotine, an oral, once-daily investigational compound being developed for the treatment of acromegaly and carcinoid syndrome.

Crinetics Announces December 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 94,000 shares of its common stock to six new non-executive employees